126 related articles for article (PubMed ID: 24137409)
1. Expression and clinical significance of cyclin kinase subunit 2 in colorectal cancer.
Yu M; Zhong M; Qiao Z
Oncol Lett; 2013 Sep; 6(3):777-780. PubMed ID: 24137409
[TBL] [Abstract][Full Text] [Related]
2. Expression of cyclin kinase subunit 2 in human breast cancer and its prognostic significance.
Wang J; Xu L; Liu Y; Chen J; Jiang H; Yang S; Tan H
Int J Clin Exp Pathol; 2014; 7(12):8593-601. PubMed ID: 25674223
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance and expression of cyclin kinase subunits 1 and 2 in hepatocellular carcinoma.
Shen DY; Fang ZX; You P; Liu PG; Wang F; Huang CL; Yao XB; Chen ZX; Zhang ZY
Liver Int; 2010 Jan; 30(1):119-25. PubMed ID: 19845855
[TBL] [Abstract][Full Text] [Related]
4. Up-regulated CKS2 promotes tumor progression and predicts a poor prognosis in human colorectal cancer.
Yu MH; Luo Y; Qin SL; Wang ZS; Mu YF; Zhong M
Am J Cancer Res; 2015; 5(9):2708-18. PubMed ID: 26609478
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of overexpressed cyclin-dependent kinase subunits 1 and 2 in esophageal carcinoma.
Wang JJ; Fang ZX; Ye HM; You P; Cai MJ; Duan HB; Wang F; Zhang ZY
Dis Esophagus; 2013; 26(7):729-36. PubMed ID: 23301842
[TBL] [Abstract][Full Text] [Related]
6. Cyclin-Dependent Kinase Regulatory Subunit 2 Indicated Poor Prognosis and Facilitated Aggressive Phenotype of Hepatocellular Carcinoma.
Zhang J; Song Q; Liu J; Lu L; Xu Y; Zheng W
Dis Markers; 2019; 2019():8964015. PubMed ID: 31781310
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological and biological significance of CDC28 protein kinase regulatory subunit 2 overexpression in human gastric cancer.
Tanaka F; Matsuzaki S; Mimori K; Kita Y; Inoue H; Mori M
Int J Oncol; 2011 Aug; 39(2):361-72. PubMed ID: 21617860
[TBL] [Abstract][Full Text] [Related]
8. Cyclin-dependent kinase subunit 2 overexpression promotes tumor progression and predicts poor prognosis in uterine leiomyosarcoma.
Deng Y; Han Q; Mei S; Li H; Yang F; Wang J; Ge S; Jing X; Xu H; Zhang T
Oncol Lett; 2019 Sep; 18(3):2845-2852. PubMed ID: 31452763
[TBL] [Abstract][Full Text] [Related]
9. Aberrant expression of CKS2 induced by ELK1 contributes to malignant progression of pancreatic cancer.
Chen Q; Fu Y; Liu X; Wang P; Dai S; Zhu F; Liu T; Xu W; Wu J
Mol Carcinog; 2023 Dec; 62(12):1947-1959. PubMed ID: 37642304
[TBL] [Abstract][Full Text] [Related]
10. Clinical and biological impact of cyclin-dependent kinase subunit 2 in esophageal squamous cell carcinoma.
Kita Y; Nishizono Y; Okumura H; Uchikado Y; Sasaki K; Matsumoto M; Setoyama T; Tanoue K; Omoto I; Mori S; Owaki T; Ishigami S; Nakagawa H; Tanaka F; Mimori K; Mori M; Natsugoe S
Oncol Rep; 2014 May; 31(5):1986-92. PubMed ID: 24604089
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-7 inhibits proliferation, migration and invasion of thyroid papillary cancer cells via targeting CKS2.
Hua K; Jin J; Zhang H; Zhao B; Wu C; Xu H; Fang L
Int J Oncol; 2016 Oct; 49(4):1531-1540. PubMed ID: 27633373
[TBL] [Abstract][Full Text] [Related]
12. CKS2 promotes tumor progression and metastasis and is an independent predictor of poor prognosis in epithelial ovarian cancer.
Xu JH; Wang Y; Xu D
Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3225-3234. PubMed ID: 31081074
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of CKS2 and CD47 expression in patients with gastric cancer who underwent radical gastrectomy.
Zhou Y; Zeng J; Zhou W; Wu K; Tian Z; Shen W
Scand J Immunol; 2022 Oct; 96(4):e13198. PubMed ID: 35703112
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of the cycline kinase subunit CKS2 increases cell proliferation rate in gastric cancer.
Kang MA; Kim JT; Kim JH; Kim SY; Kim YH; Yeom YI; Lee Y; Lee HG
J Cancer Res Clin Oncol; 2009 Jun; 135(6):761-9. PubMed ID: 19034516
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of CKS2 is associated with a poor prognosis and promotes cell proliferation and invasion in breast cancer.
Huang N; Wu Z; Hong H; Wang X; Yang F; Li H
Mol Med Rep; 2019 Jun; 19(6):4761-4769. PubMed ID: 30957190
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic potential of cyclin kinase subunit-2 in cholangiocarcinoma.
Shen DY; Zhan YH; Wang QM; Rui G; Zhang ZM
Liver Int; 2013 Jan; 33(1):137-48. PubMed ID: 23121546
[TBL] [Abstract][Full Text] [Related]
17. Expression of CKS2 in Hepatocellular Carcinoma: Correlation with Survival Outcomes and Immune Microenvironment.
Zhi R; Hao P; Li W; Zhao H
J Hepatocell Carcinoma; 2023; 10():1767-1784. PubMed ID: 37841370
[TBL] [Abstract][Full Text] [Related]
18. Identification of
Qiu D; Cai H; Liang J; Wang Z; Song F; Jiang Y; Tan R; Hou J
Transl Cancer Res; 2023 Sep; 12(9):2276-2293. PubMed ID: 37859732
[TBL] [Abstract][Full Text] [Related]
19. Cyclin-Dependent Kinase Subunit 2 (CKS2) as a Prognostic Marker for Stages I-III Invasive Non-Mucinous Lung Adenocarcinoma and Its Role in Affecting Drug Sensitivity.
Feng J; Hu M; Li Z; Hu G; Han Y; Zhang Y; Zhang M; Ren J
Cells; 2022 Aug; 11(16):. PubMed ID: 36010686
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological value of the upregulation of cyclin-dependent kinases regulatory subunit 2 in osteosarcoma.
Mo C; Wu Y; Ma J; Xie L; Huang Y; Xu Y; Peng H; Chen Z; Zeng M; Mao R
BMC Med Genomics; 2022 Apr; 15(1):81. PubMed ID: 35410253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
